Financials SNDL Inc.

Equities

SNDL

CA83307B1013

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
2.01 USD +3.08% Intraday chart for SNDL Inc. +7.49% +22.56%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 415.5 553.8 1,502 670 565.9 723.9 - -
Enterprise Value (EV) 1 565 488.1 922.6 512.4 565.9 723.9 723.9 723.9
P/E ratio -1.23 x -0.55 x -6.09 x -1.94 x -3.24 x -39.3 x 55 x -
Yield - - - - - - - -
Capitalization / Revenue 5.48 x 9.09 x 26.8 x 0.94 x 0.62 x 0.74 x 0.67 x 0.58 x
EV / Revenue 5.48 x 9.09 x 26.8 x 0.94 x 0.62 x 0.74 x 0.67 x 0.58 x
EV / EBITDA -12.4 x -21.6 x 46.8 x -42.4 x 19.4 x 16.6 x 9.66 x -
EV / FCF -1.27 x -9.15 x -9.43 x -38.6 x -19.6 x -299 x -55.3 x -
FCF Yield -78.9% -10.9% -10.6% -2.59% -5.09% -0.33% -1.81% -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 10,629 91,900 205,599 236,600 260,490 263,084 - -
Reference price 2 39.09 6.026 7.306 2.832 2.172 2.752 2.752 2.752
Announcement Date 3/30/20 3/18/21 4/27/22 4/24/23 3/21/24 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 75.86 60.92 56.13 712.2 909 978.9 1,076 1,246
EBITDA 1 -33.61 -25.58 32.09 -15.8 29.2 43.71 74.9 -
EBIT 1 -78.8 -185.4 -132.1 -347.8 -162.8 -9.2 22.9 -
Operating Margin -103.87% -304.35% -235.41% -48.83% -17.91% -0.94% 2.13% -
Earnings before Tax (EBT) -276.3 -206.3 -232.5 -379.8 - - - -
Net income 1 -271.5 -239.7 -230.4 -335.1 -172.7 -18.9 12.8 -
Net margin -357.85% -393.45% -410.46% -47.05% -18.99% -1.93% 1.19% -
EPS 2 -31.70 -11.00 -1.200 -1.460 -0.6700 -0.0700 0.0500 -
Free Cash Flow 1 -327.9 -60.52 -159.2 -17.38 -28.81 -2.42 -13.1 -
FCF margin -432.24% -99.35% -283.69% -2.44% -3.17% -0.25% -1.22% -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/30/20 3/18/21 4/27/22 4/24/23 3/21/24 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 14.37 22.72 17.6 223.7 230.5 240.4 202.5 - 248.4 209.3 246.5 248.7 259.3
EBITDA 1 10.54 18.42 -0.675 -25.93 18.32 -7.549 7.415 - 3.479 2.8 11.9 11.8 15.3
EBIT -14.02 -44 -23.17 -81.42 -88.54 -154.6 -29.68 - -84.94 - - - -
Operating Margin -97.55% -193.67% -131.67% -36.4% -38.41% -64.33% -14.66% - -34.19% - - - -
Earnings before Tax (EBT) 1.253 -46.97 -38.04 -75.76 -105.8 -160.2 -34.78 - - - - - -
Net income 11.31 -54.99 -37.9 -73.3 -98.11 -125.8 -34.2 -21.78 -82.79 - - - -
Net margin 78.73% -242.04% -215.4% -32.77% -42.56% -52.33% -16.89% - -33.32% - - - -
EPS 2 0.0500 -0.3000 -0.2000 -0.3100 -0.4100 -0.5400 -0.1400 -0.0800 -0.3200 -0.0600 - - -0.0100
Dividend per Share - - - - - - - - - - - - -
Announcement Date 11/11/21 4/27/22 5/16/22 8/12/22 11/14/22 4/24/23 5/15/23 11/13/23 3/21/24 - - - -
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 150 - - - - - - -
Net Cash position - 65.7 580 158 - - - -
Leverage (Debt/EBITDA) -4.449 x - - - - - - -
Free Cash Flow 1 -328 -60.5 -159 -17.4 -28.8 -2.42 -13.1 -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 138 3.02 3.79 10.7 7.85 10.8 26.5 -
Capex / Sales 182.09% 4.96% 6.76% 1.5% 0.86% 1.1% 2.46% -
Announcement Date 3/30/20 3/18/21 4/27/22 4/24/23 3/21/24 - - -
1CAD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.752 CAD
Average target price
4.92 CAD
Spread / Average Target
+78.79%
Consensus